Literature DB >> 9388128

Effects of lovastatin on the immune system.

M F Muldoon1, J D Flory, A Marsland, S B Manuck, T L Whiteside, B Rabin.   

Abstract

Laboratory investigations have demonstrated that blockade of HMG-CoA reductase in vitro reduces lymphocyte proliferation in response to mitogens as well as other facets of the immune system, such as natural killer cell cytotoxicity. However, in this randomized and double-blind clinical investigation, treatment with 20-mg lovastatin for 6 months did not significantly alter several enumerative and functional characteristics of circulating immune cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9388128     DOI: 10.1016/s0002-9149(97)00695-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

Authors:  Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection.

Authors:  Liza J Raggatt; Nicola C Partridge
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Kirsten Ward; Theresa Hm Moore; Margaret Burke; George Davey Smith; Juan-Pablo Casas; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

4.  Innate and Acquired Cellular Immunity in Children with Familial Hypercholesterolemia Treated with Simvastatin.

Authors:  Radosław Motkowski; Marek Alifier; Paweł Abramowicz; Jerzy Konstantynowicz; Bożena Mikołuć; Anna Stasiak-Barmuta
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

5.  Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.

Authors:  J Sellner; I Greeve; O Findling; D Grandgirard; S L Leib; H P Mattle
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

Review 6.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 7.  Management of hyperlipidaemia associated with heart transplantation.

Authors:  Klaus Wenke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].

Authors:  O Neuhaus; H Wiendl; B C Kieseier; J J Archelos; H-P Hartung
Journal:  Nervenarzt       Date:  2003-08       Impact factor: 1.214

Review 9.  Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

Authors:  A Faggiotto; R Paoletti
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.